NCT01004042View on ClinicalTrials.gov

Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2010

Conditions
DepressionQuality of Life
Interventions
DRUG

Botulinum Toxin Type A

Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.

Trial Locations (1)

90570 040

Brazilian Center for Studies in Dermatology, Porto Alegre

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Brazilan Center for Studies in Dermatology

OTHER